


Figure 1




Figure 2




Figure 3




Figure 4



MD-16 LOCF
Effect of EPS on improvements of negative symptoms
(Lenert 4+6 subgroup)
All patients
CAR 1.5-4.5 mg (n=88)
Patients without EPS
CAR 1.5-4.5 mg (n=71)
PANSS NFS change from baseline at week 6
0,00
0,10
0,20
0,30
0,40
0,50
0,60
0,70
0,80
0,90
1,00
0,86
0,88

Figure 5